Get started
Author

Alex N. O. Dodoo

Observed names: A NO Dodoo, A.N.O. Dodoo, Alex Dodoo, Alex N O Dodoo, Alex NO Dodoo, Alex No Dodoo, Dodoo, Alex
OpenAlex ID: A5111490529
Pharmacovigilance in resource-limited countries
2015 · Sten Olsson, Shanthi N Pal, et al. · Expert Review of Clinical Pharmacology · 183
Pharmacovigilance in developing countries
2007 · Munir Pirmohamed, Kwame N Atuah, et al. · BMJ · 101
PDF
A Global Perspective on Vaccine Safety and Public Health: The Global Advisory Committee on Vaccine Safety
2004 · Peter I. Folb, Ewa Bernatowska, et al. · American Journal of Public Health · 91
Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base
2009 · Olivier Bouchaud, Patrick Imbert, et al. · Malaria Journal · 76
PDF
Self-reported use of anti-malarial drugs and health facility management of malaria in Ghana
2007 · Kwame O Buabeng, Mahama Duwiejua, et al. · Malaria Journal · 62
PDF
Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences
2018 · H. Hilda Ampadu, Jarno Hoekman, et al. · Globalization and Health · 46
PDF
Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring
2011 · Andrea Kuemmerle, Alex NO Dodoo, et al. · Malaria Journal · 42
PDF
Barriers to healthcare workers reporting adverse events following immunization in four regions of Ghana
2019 · Jane F. Gidudu, Anna Shaum, et al. · Vaccine · 39
PDF
Guide to active vaccine safety surveillance: Report of CIOMS working group on vaccine safety – executive summary
2017 · U. Heininger, K. Holm, et al. · Vaccine · 33
A review of the safety of niclosamide, pyrantel, triclabendazole and oxamniquine
2008 · D. Ofori-Adjei, A.N.O. Dodoo, et al. · International Journal of Risk & Safety in Medicine · 23
PDF
Global Pharmacovigilance for Antiretroviral Drugs: Overcoming Contrasting Priorities
2011 · Nyasha Bakare, Ivor Ralph Edwards, et al. · PLoS Medicine · 22
PDF
Education and training for medicines development, regulation, and clinical research in emerging countries
2015 · Sandor Kerpel-Fronius, Bernd Rosenkranz, et al. · Frontiers in Pharmacology · 17
PDF
Optimising reporting of adverse events following immunisation by healthcare workers in Ghana: A qualitative study in four regions
2022 · Raymond Akawire Aborigo, Paul Welaga, et al. · PLoS ONE · 13
PDF
Adverse drug reactions in Ghanaian children: review of reports from 2000 to 2012 in VigiBase
2015 · Kennedy Obebi Cliff-Eribo, Imti Choonara, et al. · Expert Opinion on Drug Safety · 10
PDF
The affordable medicines facility-malaria—A success in peril
2012 · Ambrose O Talisuna, Seraphine Adibaku, et al. · Malaria Journal · 9
PDF
Considerations for unblinding individual study participants during vaccine trials
2023 · Neal Halsey, Stephen Evans, et al. · Vaccine · 1
Intensive Monitoring of Adverse Events (AE) to Antiretroviral Drugs (ARV) in Ghana
2007 · A Appiah-Danquah, A NO Dodoo, et al. · Drug Safety · 1
Implementation Science for Effective Risk Management of Medicines: A Call for Global Action
2026 · Meredith Y. Smith, Priya Bahri, et al. · Drug Safety
PDF
Improving pharmacovigilance worldwide
2017 · Alex Dodoo, Eugène van Puijenbroek
Development of a Simplified Procedure for Assessing the Effectiveness of a Spontaneous Reporting ADR System in Resource Limited Settings
2007 · J Nee-Whang, T Ofori, et al. · Drug Safety
Intensive Safety Monitoring of HAART during PMTCT in Ghana
2007 · F Zigah, A NO Dodoo, et al. · Drug Safety
Lapdap ® – A threat or an opportunity?
2005 · A.N.O. Dodoo · International Journal of Risk & Safety in Medicine
Lapdap® – A threat or an opportunity?
2005 · A.N.O. Dodoo · International Journal of Risk & Safety in Medicine
Works count: 30
Citation count: 769
H-index: 13
I10-index: 14
Year
Topic
Type